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Abstract Multiple sclerosis (MS) is a possible cause of
secondary osteoporosis. In this phase II trial we assessed
whether a weekly dose of 20,000 IU vitamin D3 prevents
bone loss in ambulatory persons with MS age 18–50 years.
ClinicalTrials.gov ID NCT00785473. All patients managed
at the University Hospital of North Norway who fulﬁlled
the main inclusion criteria were invited to participate in this
double-blinded trial. Participants were randomised to
receive 20,000 IU vitamin D3 or placebo once a week and
500 mg calcium daily for 96 weeks. The primary outcome
was the effect of the intervention on percentage change in
bone mineral density (BMD) at the hip, the spine, and the
ultradistal radius over the study period. Of 71 participants
randomised, 68 completed. Mean serum 25-hydroxyvitamin
D [25(OH)D] levels in the intervention group increased
from 55 nmol/L at baseline to 123 nmol/L at week 96. After
96 weeks, percentage change in BMD did not differ
between groups at any site. BMD decreased at the hip, by
1.4% in the placebo group (95% CI -2.3 to -0.4, SD 2.7,
p = 0.006) and by 0.7% in the treatment group (-1.6 to 0.2,
2.7, p = 0.118), difference 0.7% (-1.9 to 0.7, p = 0.332).
Findings were not altered by adjustment for sex or serum
25(OH)D. Supplementation with 20,000 IU vitamin D3 a
week did not prevent bone loss in this small population.
Larger studies are warranted to assess the effect of vitamin
D on bone health in persons with MS.
Keywords Multiple sclerosis  Clinical trials randomised
controlled (CONSORT agreement)  Osteoporosis 
Bone mineral density  25-Hydroxyvitamin D
Introduction
Multiple sclerosis (MS), a neuroinﬂammatory disease, is a
possible cause of secondary osteoporosis [17]. In persons
with MS, low bone mineral density (BMD) is more pre-
valent when compared with controls [10, 27, 37, 38] and
with reference databases [26, 35, 39].
In individuals, BMD is primarily determined by genetic
and hormonal factors, BMI, physical activity, and intake of
calcium and vitamin D [22, 29]. Peak bone mass is attained
in the third decade of life. Age-related bone loss starts
around the age of 40 in both men and women, accelerating
around menopause in women [29]. Low bone mass may
result from either inadequate peak bone mass acquisition,
bone loss, or a combination of these.
In persons with MS, several studies have shown that
BMD decreases as disability increasingly limits physical
activity [10, 26, 27, 38, 39]. Baseline data from this study
showed that one out of four participants had lower than
expected BMD for sex and age [35].
The optimal serum 25-hydroxyvitamin D [25(OH)D]
value for bone health is not known, but many scientists and
clinicians recommend maintaining 25(OH)D levels of at
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DOI 10.1007/s00415-011-5980-6least 75 nmol/L [4, 12, 24]. This is also the level of optimal
intestinal absorption of calcium and the level at which
serum parathyroid hormone levels are not further sup-
pressed by increasing vitamin D intake [19].
Most studies in persons with MS have reported mean
serum levels of vitamin D between 50 and 65 nmol/L [20].
Low vitamin D levels may contribute to poor bone health,
even before disability limits physical activity. If it proves
true that vitamin D has a role in MS aetiology and patho-
genesis, a shared pathway in the pathogenesis of MS and
osteoporosis is conceivable [1, 20]. In this phase II clinical
trial, we aimed to assess whether a weekly dose of
20,000 IU vitamin D3 prevents bone loss in fully ambula-
tory persons with MS age 18–50 years.
Methods
Trial design
This was a single centre, balanced randomised, double-
blinded, placebo-controlled, parallel-group, 96 week study
following a pre-deﬁned protocol. The study was conducted
at the Department of Neurology, University Hospital of
North Norway, the only neurology service in Troms and
Finnmark, the northernmost counties of Norway. The study
was approved by the Regional Committee for Medical and
Health Research Ethics. All participants provided written
informed consent. The trial was registered in Clinical-
Trials.gov (ID NCT00785473).
Participants
Patients were eligible for inclusion if they were
18–50 years of age with clinical deﬁnite MS according to
McDonald criteria and an Expanded Disability Status Scale
(EDSS) score B4.5 [21, 23]. Exclusion criteria were:
inability to walk 500 m or more; history of conditions or
diseases affecting bone; pregnancy or lactating during the
past 6 months; use of bone-active medications other than
intravenous methylprednisolone for treatment of relapses;
a history of nephrolithiasis during the previous 5 years;
menopause deﬁned by not having regular menstruation;
unwillingness to use appropriate contraception. A preg-
nancy test (HCG in serum) was performed in all female
participants at screening. The ﬂow of participants through
the study is shown in Fig. 1.
Randomisation
A statistician at the Clinical Research Centre, who was not
otherwise involved in the study, performed the randomi-
sation by blocks of six, stratiﬁed by sex, with a concealed,
computer-generated randomisation procedure. An identiﬁ-
cation number and a randomisation number were created
for each participant. All study personnel and participants
were blinded to treatment assignment for the duration of
the study.
Intervention
Active treatment was 20,000 IU vitamin D3 (cholecalcif-
erol) once a week, administered as a capsule of Dekristol
TM
(Mibe GmbH Arzneimittel, Brehna, Germany). Identical
placebo capsules were provided by the manufacturer of
Dekristol
TM
(SWISS CAPS AG, Kirchberg, Switzerland).
Participants were allowed to continue vitamin D supple-
ments they used at baseline. All participants received
500 mg elemental calcium daily, administered as a chew-
able tablet of Weifa Kalsium
TM
(calcium carbonate, Weifa
AS, Oslo, Norway). Participants who had gastrointestinal
side effects attributed to Weifa calcium discontinued the
calcium supplement if they had an estimated dietary cal-
cium intake of C800 mg/day. If calcium intake was lower,
they switched to Calcium Sandoz
TM
effervescent tablets
(calcium lactate-gluconate and calcium carbonate, Sandoz
A/S, Odense, Denmark) which were better tolerated.
Adherence and safety
The participants were offered a reminder to take the study
medication by weekly SMS. Adherence to study medica-
tion was evaluated by capsule counting (Adherence
(%) = (number of capsules consumed/number of capsules
that should have been consumed) 9 100). The participants
were considered adherent if they had taken at least 80% of
the study medication. Participants were educated about
clinical signs of hypercalcaemia, and ionised serum cal-
cium was determined every 12 weeks. Adverse events
were assessed every 12 weeks by phone, at study visits
weeks 48 and 96, and in case of hospital admissions.
Serious adverse events and unexpected medical events
were reported to the Norwegian Medicines Agency and to
the Ethical Committee.
Data collection
Study visits were conducted at the University Hospital of
North Norway (Clinical Trial Unit and Department of
Neurology).
Clinical examination
M.K., L.H.S. or S.I.M. performed a full physical exami-
nation and complete neurological status from which
Kurtzke’s Expanded Disability Status Scale (EDSS) was
J Neurol (2011) 258:1624–1631 1625
123determined at each study visit [21]. Standing height and
body weight were measured with participants wearing
lightweight clothing and no shoes.
Dual-energy X-ray absorptiometry (DXA)
Measurement of BMD at the hip (mean of left and right
total hip), the spine (anterior–posterior spine L1–L4), and
the non-dominant ultradistal (UD) radius by DXA was
performed by trained technicians using a Lunar Prodigy
advanced densitometer (Lunar Radiation Corp., Madison,
WI, USA.). The long-term precision was 0.26–0.28%,
obtained by daily calibration of the densitometer.
Blood tests
Every 12 weeks, routine blood tests including ionised
calcium were performed. Serum was collected for mea-
surement of 25(OH)D. At week 96 serum testosterone and
sex hormone-binding globulin (SHBG) were measured in
men and FSH in women. FSH values of C40 IU/L were
deﬁned as a marker for perimenopause [16, 32]. All labo-
ratory tests except serum 25(OH)D, were performed at the
Department of Clinical Chemistry, University Hospital of
North Norway. Batch analysis of serum 25(OH)D con-
centrations by mass spectroscopy [15] was performed at the
Hormone Laboratory, Haukeland University Hospital,
Bergen, Norway.
Outcomes
We assessed the effect of the intervention on percentage
change in BMD at the hip, the spine, and the UD radius
over the 96 week study period. Occurrence of fractures was
registered every 3 months. Analyses were carried out
according to a pre-established analysis plan. The modiﬁed
intention-to-treat population included all participants who
had received at least one dose of the study medication and
Patients identified by chart review and invited to participate (November 2007, n=153)
66 excluded 
￿ 53 did not respond or declined to participate
￿ 13 did not meet inclusion criteria
Combined screening and baseline visit (January/February 2008, n=87)
16 did not meet inclusion criteria
71 randomized (April 2008)
35 allocated to vitamin D3 20,000 IU a week
and 500 mg calcium daily
36 allocated to a weekly placebo capsule
and 500 mg calcium daily
None lost to follow-up
Three discontinued study medication before 
week 48 due to personal reasons.
One discontinued study medication at 
week 60 due to pregnancy
s i s y l a n a   t a e r t   o t   n o i t n e t n i   n i   d e d u l c n i   3 3 s i s y l a n a   t a e r t   o t   n o i t n e t n i   n i   d e d u l c n i   5 3
Analysis
Allocation
Follow-up week 48 (February/March 2009, n=68)
Follow-up week 96 (January/February 2010, n=67)
Enrollment
Fig. 1 Flow of the participants through the study
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123presented at one follow up visit. In the patient who dis-
continued the study medication because of pregnancy, the
last measurements (week 48) were carried forward.
Statistical analysis
Distribution and variance of BMD and vitamin D values
were assessed by appropriate tests. Interactions between
sex and treatment group were tested for. Differences in
baseline variables between the groups were assessed
by independent T-test for continuous variables and by
Chi-Square test for categorical variables. The main out-
come, percentage of change in BMD, was analysed by
independent sample T-test. Changes in BMD from baseline
to week 96 were analysed by paired samples T-test.
A preplanned multiple regression model included the
variables age, BMI, baseline BMD, baseline 25(OH)D,
percentage change in 25(OH)D, and perimenopausal FSH
values. Subgroup analyses were performed by sex and by
treatment group. All statistical analyses were conducted
using SPSS 16.0 for Windows. p values \0.05 were con-
sidered statistically signiﬁcant.
Results
Figure 1 shows the ﬂow of participants through the study.
Sixteen persons who were examined at the combined
screening and baseline visit did not fulﬁl the inclusion
criteria: EDSS [4.5 (5), history of nephrolithiasis (4),
lactating or planning pregnancy (4), primary progressive
MS (1), rheumatoid arthritis (1), and menopause (1). Of 71
persons who were randomised, 35 completed in the inter-
vention group (24 women, 11 men), and 33 completed in
the placebo group (24 women, 9 men). Three participants
withdrew from the study for personal reasons before the
ﬁrst follow up examination.
Adherence to study medication use and adverse events
By capsule count, all subjects were C80% (mean 98%,
range 80–100%) adherent. One participant in the placebo
group discontinued the study medication at week 94
because of nephrolithiasis. One participant in each treat-
ment arm experienced an unexpected medical event that
was not related to the study medication.
Baseline characteristics of study participants
Baseline demographic and clinical characteristics did not
differ between groups (Table 1).
BMD measurements
Table 2 shows BMD values at baseline, BMD at week 96,
and change in BMD over the study period. The values were
normally distributed. Analysis of variance (ANOVA)
showed no interactions between treatment group and sex.
Percentage change in BMD did not differ between partic-
ipants who had received vitamin D3 and those who had
received placebo. This result was not altered by adjustment
for baseline serum 25(OH)D or change in serum 25(OH)D
over the study period. At the hip, BMD decreased by 1.4%
in the placebo group (95% CI -2.3 to -0.4, SD 2.7,
p = 0.006) and by 0.7% in the treatment group (95% CI
-1.6 to 0.2, SD 2.7, p = 0.118). Women in the placebo
group had the highest bone loss at the hip. This result
persisted when women in presumed late menopausal tran-
sition (FSH C40 nmol/L) at the end of the study were
excluded. Respective changes at the spine were a decrease
Table 1 Baseline
demographical and clinical
characteristics
* As described earlier [35]
Placebo n = 33 Vitamin D3 n = 35
Sex (% women) 72.7 68.6
Age (years), mean (range) 41.0 (26–50) 39.7 (21–50)
BMI (kg/m
2), mean (range) 26.4 (18.4–39.9) 25.9 (21.0–40.7)
Duration of MS from ﬁrst symptom,
years, mean (range)
10.0 (2.0–26.0) 10.9 (1.0–27.0)
EDSS, median (range) 2.0 (0–4.5) 2.5 (0–4.5)
Intravenous methylprednisolone*
Ever treated (%) 39.4 37.1
Cumulative dose (g), mean (range) 7.9 (3.0–33.0) 13.8 (3.0–43.0)
Disease modifying treatment* interferon beta (%) 45.5 45.7
Vitamin D intake as recommended*
(C7.5 lg from diet and supplements), %
57.6 48.6
Calcium intake as recommended*
(C800 mg from diet and supplements), %
39.4 40.0
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123by 0.1% (95% CI -1.3 to 1.2, SD 3.6), and 0.3% (95% CI
-1.2 to 0.7, SD 2.7) and at the UD radius an increase by
1.3% (95% CI -0.7 to 3.3, SD 5.7) and 2.3% (95% CI
0.3–4.2, SD5.7). BMD at the hip in women was the only
baseline characteristic that differed between treatment arms
(mean (SD), placebo: 965 mg/cm
2 (132), vitamin D3:
1,039 mg/cm
2 (80), p = 0.023). No fractures occurred
during the study period.
Intercorrelations among independent variables
There were no signiﬁcant associations between percentage
change in BMD and possible predictors of BMD (sex, age,
BMI, baseline BMD, baseline serum 25(OH)D, change
serum 25(OH)D, serum testosterone in men at week 96,
and EDSS). Percent change in BMD indicated signiﬁcantly
higher bone loss in women with FSH values C40 IU/L
indicating perimenopause, compared with women with
FSH\40 IU/L: hip FSH C40 IU/L: -4.4% (SD 2.3), hip
FSH\40 IU/L: -0.7% (SD 2.3), difference -3.7%, 95%
CI -1.7 to -5.7, p\0.001; spine FSH C40 IU/L: -3.5%
(SD 3.0), spine FSH\40 IU/L: 0.2% (SD 2.8), difference
-3.7%, 95% CI -1.3 to -6.1, p = 0.003; UD radius FSH
C40 IU/L: -2.3% (SD 4.5), UD radius FSH \40 IU/L:
2.5% (SD 6.0), difference -4.8%, 95% CI -0.1 to -9.6,
p = 0.047. Baseline serum 25(OH)D did not differ
between sexes and did not correlate with BMI or age.
Blood tests
Table 3 shows values of serum 25(OH)D and ionised cal-
cium at baseline and at week 96. An unexplained decrease
of serum 25(OH)D occurred in one participant treated with
vitamin D3 (from 127 nmol/L at baseline to 48 nmol/L at
week 96). All measured values of PTH and ionised calcium
were within the respective reference ranges (1.1–6.8 pmol/L
and 1.10–1.34 mmol/L). ALP values were unchanged. FSH
in women and testosterone and SHBG in men did not differ
between groups. At week 96, seven women (ﬁve in the
placebo group and two in the vitamin D3 group) probably
were (peri) menopausal, having FSH values C40 IU/L.
Discussion
A weekly dose of 20,000 IU vitamin D3 administered for
96 weeks did not affect BMD in fully ambulatory persons
with MS age 18–50. Findings did not vary by sex and were
not altered after adjustment for serum 25(OH)D. Optimal
25(OH)D levels of C75 nmol/L were reached in 32 out of
35 participants who received vitamin D3.
Serum 25(OH)D levels, at least up to 75 nmol/L, are
strongly associated with higher BMD in young, healthy
individuals [5]. There is also good evidence that vitamin D
supplementation increases 25(OH)D concentrations and
improves bone health [6, 11]. A meta-analysis concluded
that the effect of vitamin D supplementation on bone health
was greater in persons with low (\25 nmol/l) serum
25(OH)D than those whose serum level was normal [36].
Only three individuals in the intervention group of this
study were overtly vitamin D deﬁcient at baseline
(25(OH)D\25 nmol/L), and participants were allowed to
continue vitamin D supplements they used at baseline, both
of which could have contributed to the negative ﬁndings in
this trial. In women, baseline BMD at the hip was signif-
icantly higher in the intervention than in the placebo group,
Table 2 Bone mineral density
(BMD) at baseline and at week
96, and change in BMD
* Change in BMD signiﬁcantly
different from zero, p\0.05
Placebo
n = 33, mean (SD)
Vitamin D3
n = 35, mean (SD)
Difference (95% CI) p-value
Total hip
BMD (mg/cm
2) baseline 969 (120) 1,019 (99) -50 (-103 to 3) 0.064
BMD (mg/cm
2), week 96 956 (124) 1,012 (106) -56 (-112 to 0) 0.050
BMD change (mg/cm
2) -13 (25) -7 (27) -6( -18 to 7) 0.361
BMD change (%) -1.4* (2.7) -0.7 (2.7) -0.7 (-1.9 to 0.7) 0.332
Lumbar spine
BMD (mg/cm
2), baseline 1,166 (136) 1,205 (118) -39 (-101 to 22) 0.203
BMD (mg/cm
2), week 96 1,165 (143) 1,202 (121) -37 (-101 to 27) 0.255
BMD change (mg/cm
2) -1 (42) -3 (31) 3 (-15 to 21) 0.769
BMD change (%) -0.1 (3.6) -0.3 (2.7) 0.2 (-1.3 to 1.7) 0.793
UD radius
BMD (mg/cm
2), baseline 473 (81) 485 (67) -12 (-48 to 24) 0.503
BMD (mg/cm
2), week 96 479 (85) 496 (73) -17 (-55 to 22) 0.395
BMD change (mg/cm
2) 6 (26) 11 (28) -4( -17 to 9) 0.501
BMD change (%) 1.3 (5.7) 2.3 (5.7)* -1.0 (-3.7 to 1.8) 0.506
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123which may also have inﬂuenced the result of the study. The
major limitation of this study, however, is the small num-
ber of participants. Data from BMD measurements in a
comparable group of persons with MS were not available
when the trial was planned. Based on change in BMD from
this study, a trial with approximately 250 persons in each
treatment arm would have been needed to conﬁrm or reject
the hypothesis that a weekly dose of 20,000 IU vitamin D3
administered for 96 weeks prevents bone loss in persons
with MS (two tailed test, power 80%, risk of type I error
5%, drop out rate 10%).
Supplementing 20,000 IU vitamin D3 per week
increased serum 25(OH)D by 68 nmol/L, and 32 out of 35
participants in the intervention group reached desired vita-
min D levels of C75 nmol/L. The study medication was
tolerated without clinical or biochemical side effects, and
even higher doses of vitamin D3 are probably safe [7, 33].
Supplementation with vitamin D can be achieved equally
well with daily as with weekly dosing frequencies [9].
At baseline, one quarter of our study population had
lower than expected BMD for sex and age [35]. Over the
96 week study period, BMD at the hip decreased in both
treatment arms, the change being statistically signiﬁcant in
the placebo group. This ﬁnding indicates that MS may be a
cause of secondary osteoporosis. In healthy individuals,
studies have reported no signiﬁcant bone loss at the hip in
women before the perimenopausal years [2, 3, 8, 18, 25,
32], while men may or may not have a small bone loss
before age 50 [2, 14, 18]. The general bone loss at the hip,
a weight bearing site, may result from decreased physical
activity even in fully ambulatory persons with MS [30],
due to fatigue, visual problems, and impaired balance. We
observed no change in BMD at the lumbar spine. This
ﬁnding is in agreement with two recent studies reporting
unchanged BMD at the lumbar spine over a period of
respectively 96 weeks and 39 months in interferon beta-
treated persons with MS [31, 34]. At the non-dominant UD
radius, BMD increased signiﬁcantly in the intervention
group, but not in the placebo group. In healthy individuals,
BMD at this site has been reported to be stable or
increasing up to age 40 in both sexes [8, 13, 18]. BMD at
the UD radius, especially in the non-dominant arm, is not
dependent on weight bearing activity and therefore is likely
to be less affected by mild to moderate MS-related
disability.
No fractures occurred during this study, while 22% of
more disabled persons with MS experienced low impact
fractures during a 2-year observation period in another
study [10].
The strengths of this study are its double-blinded, pop-
ulation-based design and its long follow-up. All eligible
persons with MS from a homogeneous and stable popula-
tion in a deﬁned geographical area who were willing to
participate were included. Only three out of 71 participants
were lost to follow-up and adherence to treatment was
excellent. Confounding by seasonal variations in 25(OH)D
and BMD was avoided by conducting study visits at the
end of winter. We included both women and men, because
we considered it relevant from a clinical point of view, but
there are considerable sex differences in bone metabolism,
and ﬁndings in a mixed population must be interpreted with
care.
Multiple sclerosis (MS) is the most common disease that
causes neurological disability among young Caucasians,
onset being before age 30 in half of the patients. Persons
with MS gradually experience reduced muscle strength,
problems with balance and coordination, vision problems
and fatigue, all of which are likely to result in limited
opportunity for high-impact physical activity, also early in
the course of the disease, and thus interfere with mainte-
nance of good bone health. Evidence is accumulating that
hypovitaminosis D may play a role in the aetiology and
pathogenesis of MS [28], which by itself might put persons
with MS at risk of low peak bone mass. We also found that
bone loss at the hip was higher than expected in healthy
individuals.
Supplementation with vitamin D and calcium are the
basis of osteoporosis prevention and treatment. Given that
Table 3 Serum 25(OH)D and
ionised calcium at baseline and
at week 96
** Signiﬁcant change from
baseline, p\0.01
Baseline Week 96
Placebo,
n = 33
Vitamin D3,
n = 35
Placebo,
n = 33
Vitamin D3,
n = 35
25(OH)D, nmol/L
Mean (SD) 57.3 (21.8) 55.6 (29.0) 61.8 (25.2) 123.2** (34.2)
Range 17.9–101.0 19.9–143.0 19.1–106.0 47.5–205.0
Deﬁcient (\25 nmol/L), % 9 9 12 0
Insufﬁcient (25–49 nmol/L), % 33 45 24 3
Marginal (50 to\75 nmol/L), % 33 29 33 6
Optimal (C75 nmol/L), % 24 17 30 91
Ionised calcium, mmol/L, mean (SD) 1.2 (0.0) 1.2 (0.0) 1.2 (0.0) 1.2 (0.0)
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123MS is a cause of secondary osteoporosis, vitamin D deﬁ-
ciency in a person with MS would represent an additional
risk factor. Much larger studies are needed to assess whe-
ther optimising intake of vitamin D and calcium is bene-
ﬁcial for bone health in persons with MS.
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